|本期目录/Table of Contents|

[1]张燕珍 王锡携 文小兰.血清巨噬细胞迁移抑制因子对活动性肺结核分诊检测的意义[J].中华肺部疾病杂志,2023,(02):200-202.[doi:10.3877/cma.j.issn.1674-6902.2023.02.010 ]
点击复制

血清巨噬细胞迁移抑制因子对活动性肺结核分诊检测的意义(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2023年02期
页码:
200-202
栏目:
临床研究
出版日期:
2023-04-20

文章信息/Info

Title:
-
作者:
张燕珍1 王锡携1 文小兰2
572600 海南,东方市人民医院检验科1、感染科2
Author(s):
-
关键词:
活动性肺结核;  巨噬细胞迁移抑制因子;  分类检测;  人类免疫缺陷病毒;  结核分枝杆菌;  利福平耐药
Keywords:
-
分类号:
R562
DOI:
10.3877/cma.j.issn.1674-6902.2023.02.010
摘要:
目的 分析血清巨噬细胞迁移抑制因子(MIF)作为活动性肺结核(TBpos)分诊检测的诊断效能。方法 选择2019年1月至2022年5月我院收治的肺结核(PTB)患者113例,根据诊断标准分为TBpos组63例及TBneg组50例。采用酶联免疫吸附测定法检测血清MIF水平。结果 TBpos组患者的血清MIF水平高于TBneg组[12.35(2.10,75.50)ng/ml vs. 6.50(1.60,15.15)ng/ml,P=0.030]。在TBneg组[7.40(1.70,8.40)ng/ml vs. 5.20(1.50,7.70)ng/ml,P=0.042]及TBpos组[26.90(6.20,115.00)ng/ml vs. 4.20(1.70,31.90)ng/ml,P=0.025]中人类免疫缺陷病毒(HIV)阳性(HIV+)患者的血清MIF水平高于HIV阴性(HIV-)患者。TBneg组及TBpos组患者血清MIF水平均随着患者症状总评分的增加而升高(P<0.05)。经单因素及多因素Logistic回归分析,TBpos组、痰涂片阳性、HIV+、症状总评分6～9分与血清MIF水平>6.0 ng/ml相关(P<0.05)。经受试者工作特征曲线分析,血清MIF水平对TBpos的诊断曲线下面积为0.748(95%CI:0.650～0.846),截断值为9.05 ng/ml。使用血清MIF水平≥9.05 ng/ml为诊断依据,需要进行结核分枝杆菌半巢式全自动实时荧光定量PCR检测(Xpert)的患者将减少62.0%,错过38.0%具有Xpert阳性结果的TBpos患者。血清MIF水平对高症状总评分、HIV+患者的诊断灵敏度及特异度较高(P<0.05)。结论 血清MIF水平可有助于提高TBpos诊断具有意义。
Abstract:
-

参考文献/References:

1 曹雯雯, 刘 欣, 杨 阳. 结核感染T细胞斑点试验联合胸腔积液腺苷脱氨酶检测对胸腔积液患者中活动性肺结核病的早期诊断及疗效评估价值[J]. 中国感染与化疗杂志, 2022, 22(3): 282-288.
2 任成山, 林 辉, 杨仕明. 结核病的流行特征与耐多药的窘迫及其策略[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(3): 269-274.
3 Namuganga AR, Chegou NN, Mayanja-Kizza H. Past and Present Approaches to Diagnosis of Active Pulmonary Tuberculosis[J]. Front Med(Lausanne), 2021, 8: 709793.
4 韩 伟, 崔俊伟, 黄 健, 等. 三种结核抗体联合检测对活动性肺结核的诊断价值[J]. 分子诊断与治疗杂志, 2022, 14(1): 10-13, 18.
5 Turner CT, Gupta RK, Tsaliki E, et al. Blood transcriptional biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective, observational, diagnostic accuracy study[J]. Lancet Respir Med, 2020, 8(4): 407-419.
6 李晓倩, 王智慧, 池跃朋, 等. 血清MMP-9测定、肺泡灌洗液Xpert MTB/RIF检测、INF-γ释放试验单独和联合检测对肺结核的诊断效能[J]. 检验医学, 2022, 37(1): 11-15.
7 赵 然, 姚伟娟. 巨噬细胞迁移抑制因子的功能及临床研究进展[J]. 生理科学进展, 2014,(2): 93-99.
8 Tong X, Yan Z, Zhou Q, et al. Association between the MIF-173G/C Polymorphism and Serum MIF levels with Pulmonary Tuberculosis: A Meta-analysis[J]. Sci Rep, 2017, 7(1): 234.
9 Trifone C, Baquero L, Czernikier A, et al. Macrophage migration inhibitory factor(MIF)promotes increased proportions of the highly permissive th17-like cell profile during HIV infection[J]. Viruses, 2022, 14(10): 2218.
10 Regis EG, Barreto-de-Souza V, Morgado MG, et al. Elevated levels of macrophage migration inhibitory factor(MIF)in the plasma of HIV-1-infected patients and in HIV-1-infected cell cultures: a relevant role on viral replication[J]. Virology, 2010, 399(1): 31-38.
11 Shang ZB, Wang J, Kuai SG, et al. Serum macrophage migration Inhibitory factor as a biomarker of active pulmonary tuberculosis[J]. Ann Lab Med, 2018, 38(1): 9-16.
12 肺结核诊断WS288-2017[J]. 中国感染控制杂志, 2018, 17(7): 642-652.
13 Yoon C, Semitala FC, Atuhumuza E, et al. Point-of-care C-reactive protein-based tuberculosis screening for people living with HIV: a diagnostic accuracy study[J]. Lancet Infect Dis, 2017, 17(12): 1285-1292.
14 Zepeda-Nuño JS, Gutiérrez-Cortés E, Hernández-Bello J, et al. Macrophage migration inhibitory factor: A promising oncogenic serological biomarker for oral squamous cell carcinoma[J]. Int J Immunopathol Pharmacol, 2021, 35: 20587384211038417.
15 欧喜超, 夏 辉, 李 强, 等. 结核分枝杆菌及利福平耐药核酸扩增检测成本分析[J]. 中国防痨杂志, 2013, 35(9): 723-728.
16 乐晓琴, 陈 军, 沈银忠, 等. 结核分枝杆菌/利福平耐药实时荧光定量核酸扩增检测技术诊断艾滋病患者肺结核的临床应用评价[J]. 中华传染病杂志, 2021, 39(1): 21-24.
17 De Groote MA, Sterling DG, Hraha T, et al. Discovery and validation of a six-marker serum protein signature for the diagnosis of active pulmonary tuberculosis[J]. J Clin Microbiol, 2017, 55(10): 3057-3071.
18 Samuels THA, Wyss R, Ongarello S, et al. Evaluation of the diagnostic performance of laboratory-based c-reactive protein as a triage test for active pulmonary tuberculosis[J]. PLoS One, 2021, 16(7): e0254002.
19 朱志强, 郑湘予, 张娈娈, 等. 巨噬细胞迁移抑制因子与早期急性胰腺炎的关系研究[J]. 中华危重病急救医学, 2020, 32(2): 221-225.
20 Bilsborrow JB, Doherty E, Tilstam PV, et al. Macrophage migration inhibitory factor(MIF)as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus[J]. Expert Opin Ther Targets, 2019, 23(9): 733-744.
21 Liu M, Xie Z, Sun G, et al. Macrophage migration inhibitory factor may play a protective role in osteoarthritis[J]. Arthritis Res Ther, 2021, 23(1): 59.
22 Voss S, Krüger S, Scherschel K, et al. Macrophage migration inhibitory factor(MIF)expression increases during Myocardial infarction and supports pro-inflammatory signaling in cardiac fibroblasts[J]. Biomolecules, 2019, 9(2): 38.
23 Zhang Y, Liu Z, Wang K, et al. Macrophage migration inhibitory factor regulates joint capsule fibrosis by promoting TGF-β1 production in fibroblasts[J]. Int J Biol Sci, 2021, 17(7): 1837-1850.
24 黄 琳, 马元芬, 王灵军, 等. 巨噬细胞迁移抑制因子调节寄生虫与宿主免疫系统相互作用机制的研究进展[J]. 中国血吸虫病防治杂志, 2019, 31(4): 446-449.
25 Shen D, Tang C, Zhu S, et al. Macrophage migration inhibitory factor is an early marker of severe acute pancreatitis based on the revised Atlanta classification[J]. BMC Gastroenterol, 2021, 21(1): 34.
26 Rosado Jde D, Rodriguez-Sosa M. Macrophage migration inhibitory factor(MIF): a key player in protozoan infections[J]. Int J Biol Sci, 2011, 7(9): 1239-1256.

备注/Memo

备注/Memo:
通信作者: 张燕珍, Email: zhangyanzhen2648@163.com
更新日期/Last Update: 2023-04-20